Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | SRPK1 | Q96SB4 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955868 | 1.00 | ADRA1A (0.38) | ADRA1AMAPTDRD4HTR2ATP53 | |
| SCHEMBL2957073 | 1.00 | ADRA1A (0.38) | ADRA1AMAPTDRD4HTR2ATP53 | |
| SCHEMBL2957077 | 1.00 | ADRA1A (0.38) | ADRA1AMAPTDRD4HTR2ATP53 | |
| SCHEMBL2955865 | 1.00 | ADRA1A (0.38) | ADRA1AMAPTDRD4HTR2ATP53 | |
| SCHEMBL2958105 | 0.89 | FFAR4 (0.40) | ADRA1AMAPTDRD4HTR2ATP53 | |
| SCHEMBL2965755 | 0.89 | FFAR4 (0.40) | ADRA1AMAPTDRD4HTR2ATP53 | |
| SCHEMBL2958104 | 0.89 | FFAR4 (0.40) | ADRA1AMAPTDRD4HTR2ATP53 | |
| SCHEMBL2963497 | 0.89 | FFAR4 (0.40) | ADRA1AMAPTDRD4HTR2ATP53 | |
| SCHEMBL2959377 | 0.89 | FFAR4 (0.40) | ADRA1AMAPTDRD4HTR2ATP53 | |
| SCHEMBL2963492 | 0.89 | FFAR4 (0.40) | ADRA1AMAPTDRD4HTR2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357704-B2 | Fused heterocyclic compounds as inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | claimed |
| US-20100247534-A1 | FUSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | claimed |
| US-20050250783-A1 | Fused heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | claimed |
| US-8357704-B2 | Fused heterocyclic compounds as inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-20100247534-A1 | FUSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-7772252-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772232-B2 | Quinazolinyl compounds as inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1935887-B1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMA INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-7550469-B2 | Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7521445-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1362039-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050250783-A1 | Fused heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-19 | — | — | US | disclosed |
| US-20040220173-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor | AVENTIS PHARMACEUTICAL INC. (US) | 2004-11-04 | — | — | US | disclosed |
| EP-1392676-A2 | HETEROCYCLIC UREA DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20040030137-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | disclosed |
| EP-1362039-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals, Inc. (US) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002066468-A2 | HETEROCYCLIC UREA DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002066446-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030137-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | ADRA1A 332/4885MAPT 346/4885DRD4 10/4885 |
| US-20100247534-A1 | FUSED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNH2, KCNH3, KCNB1 | ADRA1A 1172/4885MAPT 4289/4885DRD4 292/4885 |
| US-20050250783-A1 | Fused heterocyclic compounds | CCNY, CCNH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ADRA1A 1264/4885MAPT 4011/4885DRD4 19/4885 |
| US-20050107389-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | ADRA1A 313/4885MAPT 421/4885DRD4 13/4885 |
| US-20040220173-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor | DRD3, DRD2, DRD1 | ADRA1A 500/4885MAPT 257/4885DRD4 8/4885 |
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | DRD3, DRD2, HTR3C | ADRA1A 532/4885MAPT 286/4885DRD4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.